Compound profile
Also known as: GHRP analogue
A selective growth hormone secretagogue (ghrelin-receptor agonist) discussed for GH pulses with a relatively favorable selectivity profile in older literature.
Ipamorelin is a synthetic pentapeptide, a chain of five amino acids, developed by Novo Nordisk in the late 1990s as part of a medicinal chemistry program searching for growth hormone secretagogues with a cleaner selectivity profile than earlier compounds in the class. It works by activating the ghrelin receptor (GHS-R1a), the same receptor the hunger hormone ghrelin engages, which triggers the pituitary gland to release growth hormone.
What made ipamorelin notable when it was first described in 1998 was its relative selectivity. Earlier growth hormone-releasing peptides (GHRPs) tended to also raise cortisol, aldosterone, and prolactin at meaningful doses, side effects that complicated their use. Ipamorelin was reported to stimulate GH release with comparatively little effect on those other hormones, at least in the preclinical and early human pharmacology studies that were run.
Despite that promising selectivity profile, ipamorelin's clinical development did not go far. Its main completed human trial was a phase 2 study testing it for postoperative ileus, slowed bowel function after surgery, run by Helsinn Therapeutics, and it failed to meet its primary efficacy endpoint. Development was discontinued after that, and ipamorelin has never been submitted for FDA approval for any indication. Today it exists only as a research chemical, most often discussed online alongside CJC-1295 as a GH-axis pairing.
Acts at the ghrelin receptor (GHS-R1a) to provoke GH release. Often contrasted with older GHRPs that more strongly affect cortisol or prolactin in some reports.
Ipamorelin binds to and activates the ghrelin receptor on pituitary cells, prompting a pulse of growth hormone release, similar in principle to how the body's own ghrelin can stimulate GH secretion around meal times. Preclinical work in rat pituitary cells and later in vivo animal studies reported that this GH-releasing effect happened without meaningfully raising ACTH, cortisol, aldosterone, or prolactin, distinguishing it from older, less selective GHRPs like GHRP-6.
A human pharmacokinetic and pharmacodynamic study in healthy male volunteers, published in 1999, reported dose-proportional GH release following ipamorelin administration with a half-life of roughly two hours, confirming the basic pharmacology translated from animals to people, at least for the immediate GH-release effect. Because ipamorelin works upstream by prompting the pituitary's own GH-producing cells rather than supplying growth hormone directly, its effects depend on the pituitary having intact capacity to respond, and the pulsatile nature of that release is generally seen as more physiological than a constant external GH dose, though this framing comes mostly from the mechanism rather than from long-term outcome data.
Clinical pharmacology studies describe GH release with comparatively limited ACTH/cortisol effects versus some peers. Athletic outcome evidence remains thin.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Preclinical studies report GH release with minimal effect on ACTH, cortisol, aldosterone, or prolactin, a selectivity profile that distinguished it from earlier GHRPs at the time it was discovered.
The 1999 human pharmacokinetic study in healthy male volunteers found the GH response scaled with dose, establishing basic human pharmacology for the compound.
Like other GH secretagogues, ipamorelin is discussed for downstream effects associated with elevated GH and IGF-1, including recovery and body composition changes, though this extrapolates from GH physiology generally rather than from dedicated outcome trials in healthy athletic populations.
Hunger, water retention, and GH-axis downstream effects are possible class themes. Product purity and legality vary. Evidence for sleep or recovery benefits in healthy lifters is mostly anecdotal.
Ipamorelin's human evidence base is thin. Its one meaningful controlled human trial tested a surgical, clinical use, postoperative bowel function, not athletic recovery or body composition, and it failed to meet its primary endpoint, which is why Novo Nordisk and later Helsinn Therapeutics stopped developing it further. There are no published phase 3 trials, no long-term human safety studies in healthy adults, and no regulatory approval anywhere in the world for any indication. The theoretical risks associated with sustained GH-axis stimulation, water retention, increased hunger, effects on insulin sensitivity, and downstream IGF-1 elevation, apply here in principle, but dedicated data quantifying those risks specifically for ipamorelin in healthy, non-clinical populations does not really exist. Most of what circulates online about sleep, recovery, or physique benefits is anecdotal or extrapolated from broader GH physiology rather than drawn from controlled ipamorelin trials. As with other unapproved research peptides, product purity, dosing accuracy, and legal status vary by source and jurisdiction, and that sits on top of, not instead of, the underlying evidence gap.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Fitness discussions often group a GHRH analogue (CJC-1295 / Mod GRF) with ipamorelin when talking about GH-axis pulses, sleep, and recovery themes.
Pairing popularity is not evidence of synergy from large RCTs. Confirm peptide identity (e.g., DAC vs non-DAC) in any primary literature you review.
Muscle / GH axis · Sleep / recovery adjunct · Recovery
